An Overview of PET Radiochemistry, Part 2: Radiometals
暂无分享,去创建一个
Marie Brandt | Jens Cardinale | Margaret L Aulsebrook | Gilles Gasser | Thomas L Mindt | G. Gasser | J. Cardinale | T. Mindt | Margaret L. Aulsebrook | Marie R. Brandt
[1] W. Oyen,et al. Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients , 2014, BioMed research international.
[2] I. Mellinghoff,et al. Imaging Tumor Burden in the Brain with 89Zr-Transferrin , 2013, The Journal of Nuclear Medicine.
[3] Jason S. Lewis,et al. Magnitude of Enhanced Permeability and Retention Effect in Tumors with Different Phenotypes: 89Zr-Albumin as a Model System , 2011, The Journal of Nuclear Medicine.
[4] Michael S. Hofman,et al. Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system , 2011, Cancer imaging : the official publication of the International Cancer Imaging Society.
[5] Mark A Mintun,et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.
[6] K. Johnston,et al. Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging , 2016, EJNMMI Research.
[7] Theresa M Reineke,et al. Theranostics: combining imaging and therapy. , 2011, Bioconjugate chemistry.
[8] A. Jalilian,et al. The current status and future of theranostic Copper-64 radiopharmaceuticals , 2016 .
[9] R. Weissleder,et al. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. , 2011, Bioconjugate chemistry.
[10] P. Schöffski,et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.
[11] G. V. van Dongen,et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Y Yonekura,et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] G. Gasser,et al. A solid phase-assisted approach for the facile synthesis of a highly water-soluble zirconium-89 chelator for radiopharmaceutical development. , 2017, Dalton transactions.
[14] J. Ballinger. Short- and long-term responses to molybdenum-99 shortages in nuclear medicine. , 2010, The British journal of radiology.
[15] Carolyn J Anderson,et al. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. , 2009, Cancer biotherapy & radiopharmaceuticals.
[16] C. Villano,et al. 64CuCl2: New theranostic agent , 2014 .
[17] Jason S. Lewis,et al. Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO) , 2014, Journal of medicinal chemistry.
[18] M. Schwaiger,et al. The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity , 2016, EJNMMI Research.
[19] H. Haisma,et al. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[20] F. Alves,et al. Cyclotron production of Ga-68 for human use from liquid targets: From theory to practice , 2017 .
[21] A. Sanchez-Crespo,et al. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[22] A. Terzic,et al. Novel 89Zr cell labeling approach for PET-based cell trafficking studies , 2015, EJNMMI Research.
[23] D. Abou,et al. In vivo biodistribution and accumulation of 89Zr in mice. , 2011, Nuclear medicine and biology.
[24] H. Wester,et al. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals. , 2018, Journal of labelled compounds & radiopharmaceuticals.
[25] C. E. Knapp,et al. Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling , 2017, RSC advances.
[26] R. R. Conry. Copper: Inorganic & Coordination Chemistry , 2006 .
[27] H. Coenen,et al. Radiolabelling with isotopic mixtures of (52g/55)Mn(II) as a straight route to stable manganese complexes for bimodal PET/MR imaging. , 2016, Dalton transactions.
[28] H. Herzog,et al. The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y , 2017, Pharmaceuticals.
[29] A. Bauman,et al. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET , 2015, The Journal of Nuclear Medicine.
[30] Simon-Peter Williams,et al. Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for 89Zr4+ and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice , 2016, Theranostics.
[31] R. Boellaard,et al. Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients , 2006, Clinical Cancer Research.
[32] A. Majkowska,et al. Cyclotron production of 43Sc for PET imaging , 2015, EJNMMI Physics.
[33] H. Anger,et al. LOCALIZATION OF BRAIN TUMORS WITH THE POSITRON SCINTILLATION CAMERA. , 1963, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] Ido D. Weiss,et al. MicroPET Imaging of Integrin αvβ3 Expressing Tumors Using 89Zr-RGD Peptides , 2010, Molecular Imaging and Biology.
[35] Daniel L Smith,et al. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[36] R. Hicks,et al. A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies. , 2016, Chemical communications.
[37] S. Huclier-Markai,et al. Cyclotron production of high purity (44m,44)Sc with deuterons from (44)CaCO3 targets. , 2015, Nuclear medicine and biology.
[38] D. Le Guludec,et al. Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging , 2015, Front. Med..
[39] H. Herzog,et al. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] F Rösch,et al. Past, present and future of 68Ge/68Ga generators. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[41] I. Velikyan. Prospective of 68Ga-Radiopharmaceutical Development , 2013, Theranostics.
[42] G. Schmidt,et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[43] J. Engle,et al. 89Zr radiochemistry for positron emission tomography. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).
[44] Jason S. Lewis,et al. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. , 2015, Bioconjugate chemistry.
[45] Zahi A. Fayad,et al. PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles , 2015, The Journal of Nuclear Medicine.
[46] O. Boerman,et al. 89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry , 2017, Bioconjugate chemistry.
[47] D. Häussinger,et al. An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes. , 2014, Chemical communications.
[48] F. Rösch,et al. Post-elution processing of (44)Ti/(44)Sc generator-derived (44)Sc for clinical application. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.